• Something wrong with this record ?

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

A. Jonasova, R. Bokorova, J. Polak, M. Vostry, A. Kostecka, H. Hajkova, R. Neuwirtova, M. Siskova, D. Sponerova, J. Cermak, D. Mikulenkova, L. Cervinek, J. Brezinova, K. Michalova, O. Fuchs,

. 2015 ; 95 (1) : 27-34. [pub] 20141031

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16010727

Grant support
NT13836 MZ0 CEP Register

Downregulation of cereblon (CRBN) gene expression is associated with resistance to the immunomodulatory drug lenalidomide and poor survival outcomes in multiple myeloma (MM) patients. However, the importance of CRBN gene expression in patients with myelodysplastic syndrome (MDS) and its impact on lenalidomide therapy are not clear. In this study, we evaluate cereblon expression in mononuclear cells isolated from bone marrow [23 lower risk MDS patients with isolated 5q deletion (5q-), 37 lower risk MDS patients with chromosome 5 without the deletion of long arms (non-5q-), and 24 healthy controls] and from peripheral blood (38 patients with 5q-, 52 non-5q- patients and 25 healthy controls) to gain insight into, firstly, the role of cereblon in lower risk MDS patients with or without 5q deletion and, secondly, into the mechanisms of lenalidomide action. Patients with 5q- lower risk MDS have the highest levels of CRBN mRNA in comparison with both lower risk MDS without the deletion of long arms of chromosome 5 and healthy controls. CRBN gene expression was measured using the quantitative TaqMan real-time PCR. High levels of CRBN mRNA were detected in all lenalidomide responders during the course of therapy. A significant decrease of the CRBN mRNA level during lenalidomide treatment is associated with loss of response to treatment and disease progression. These results suggest that, similar to the treatment of MM, high levels of full-length CRBN mRNA in lower risk 5q- patients are necessary for the efficacy of lenalidomide.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010727
003      
CZ-PrNML
005      
20240903091142.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.12457 $2 doi
024    7_
$a 10.1111/ejh.12457 $2 doi
035    __
$a (PubMed)25284710
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jonášová, Anna $u 1st Medical Clinic, General University Hospital Prague, Prague, Czech Republic. $7 xx0103767
245    10
$a High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide / $c A. Jonasova, R. Bokorova, J. Polak, M. Vostry, A. Kostecka, H. Hajkova, R. Neuwirtova, M. Siskova, D. Sponerova, J. Cermak, D. Mikulenkova, L. Cervinek, J. Brezinova, K. Michalova, O. Fuchs,
520    9_
$a Downregulation of cereblon (CRBN) gene expression is associated with resistance to the immunomodulatory drug lenalidomide and poor survival outcomes in multiple myeloma (MM) patients. However, the importance of CRBN gene expression in patients with myelodysplastic syndrome (MDS) and its impact on lenalidomide therapy are not clear. In this study, we evaluate cereblon expression in mononuclear cells isolated from bone marrow [23 lower risk MDS patients with isolated 5q deletion (5q-), 37 lower risk MDS patients with chromosome 5 without the deletion of long arms (non-5q-), and 24 healthy controls] and from peripheral blood (38 patients with 5q-, 52 non-5q- patients and 25 healthy controls) to gain insight into, firstly, the role of cereblon in lower risk MDS patients with or without 5q deletion and, secondly, into the mechanisms of lenalidomide action. Patients with 5q- lower risk MDS have the highest levels of CRBN mRNA in comparison with both lower risk MDS without the deletion of long arms of chromosome 5 and healthy controls. CRBN gene expression was measured using the quantitative TaqMan real-time PCR. High levels of CRBN mRNA were detected in all lenalidomide responders during the course of therapy. A significant decrease of the CRBN mRNA level during lenalidomide treatment is associated with loss of response to treatment and disease progression. These results suggest that, similar to the treatment of MM, high levels of full-length CRBN mRNA in lower risk 5q- patients are necessary for the efficacy of lenalidomide.
650    _2
$a makrocytární anemie $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D000748
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a chromozomální delece $7 D002872
650    _2
$a lidské chromozomy, pár 5 $x genetika $x metabolismus $7 D002895
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x terapeutické užití $7 D007155
650    _2
$a leukocyty mononukleární $x účinky léků $x metabolismus $x patologie $7 D007963
650    _2
$a myelodysplastické syndromy $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D009190
650    _2
$a proteasy $x genetika $x metabolismus $7 D010447
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a sestřih RNA $7 D012326
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
650    _2
$a signální transdukce $7 D015398
650    _2
$a thalidomid $x analogy a deriváty $x terapeutické užití $7 D013792
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bokorova, Radka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Faculty of Science, Charles University, Prague, Czech Republic.
700    1_
$a Polák, Jaroslav $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0070555
700    1_
$a Vostrý, Martin $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0321711
700    1_
$a Kostečka, Arnošt $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0128612
700    1_
$a Hájková, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0121176
700    1_
$a Neuwirtová, Radana, $u 1st Medical Clinic, General University Hospital Prague, Prague, Czech Republic. $d 1927- $7 jk01090111
700    1_
$a Šišková, Magda $u 1st Medical Clinic, General University Hospital Prague, Prague, Czech Republic. $7 xx0103999
700    1_
$a Šponerová, Dana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0127224
700    1_
$a Čermák, Jaroslav, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1954- $7 xx0053072
700    1_
$a Mikulenková, Dana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0182877
700    1_
$a Červinek, Libor $u Leukemic Group, Faculty Hospital, Brno, Czech Republic. $7 xx0148492
700    1_
$a Březinová, Jana, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1958- $7 xx0046958
700    1_
$a Michalová, Kyra, $u Center of Oncocytogenetics, General University Hospital, Prague, Czech Republic. $d 1942- $7 nlk19990073558
700    1_
$a Fuchs, Ota $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $7 xx0060631
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 95, č. 1 (2015), s. 27-34
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25284710 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20240903091139 $b ABA008
999    __
$a ok $b bmc $g 1114156 $s 935095
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 95 $c 1 $d 27-34 $e 20141031 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
GRA    __
$a NT13836 $p MZ0
LZP    __
$a Pubmed-20160408

Find record

Citation metrics

Archiving options